InvestorsHub Logo
Followers 137
Posts 22807
Boards Moderated 0
Alias Born 04/08/2004

Re: marcusl2 post# 410

Thursday, 03/30/2017 2:14:49 AM

Thursday, March 30, 2017 2:14:49 AM

Post# of 807
Novartis says U.S. regulator grants speedy review of CAR-T cell therapy

http://www.reuters.com/article/us-novartis-cancer-filing-idUSKBN1710II

CTL019 will likely cost hundreds of thousands of dollars per patient if approved, and Novartis counts it among drugs it believes will eventually exceed $1 billion in annual sales.



Good luck and GOD bless,

George